| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T231 |
0-11 |
Sentence |
denotes |
Disclaimer: |
| T232 |
12-185 |
Sentence |
denotes |
The findings and conclusions in this report those of the authors do not necessarily represent the official positions of the Centers for Disease Control and Prevention (CDC). |
| T233 |
186-202 |
Sentence |
denotes |
Publisher's Note |
| T234 |
203-321 |
Sentence |
denotes |
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
| T235 |
323-343 |
Sentence |
denotes |
Author contributions |
| T236 |
344-443 |
Sentence |
denotes |
An expert meeting was organized by PEV, RJMB, JW and FLvdV and held in Amsterdam on April 16, 2019. |
| T237 |
444-558 |
Sentence |
denotes |
Present at the expert meeting were PEV, BJAR, RJMB, SB, CJC, OAC, DRG, NAFJ, BJK, KL, JM, MHN, TFP, TRR and FLvdV. |
| T238 |
559-675 |
Sentence |
denotes |
A first draft manuscript was prepared by PEV, BJAR, RJMB, JW and FLvdV and circulated for comments from all experts. |
| T239 |
676-729 |
Sentence |
denotes |
All experts reviewed and commented on the manuscript. |
| T240 |
730-796 |
Sentence |
denotes |
Using these comments, a final version was circulated for approval. |
| T241 |
798-805 |
Sentence |
denotes |
Funding |
| T242 |
806-842 |
Sentence |
denotes |
The meeting was supported by Pfizer. |
| T243 |
843-947 |
Sentence |
denotes |
Pfizer had no role in the topics discussed nor were they involved in drafting of the consensus document. |
| T244 |
949-982 |
Sentence |
denotes |
Compliance with ethical standards |
| T245 |
984-1005 |
Sentence |
denotes |
Conflicts of interest |
| T246 |
1006-1148 |
Sentence |
denotes |
PE Verweij reported grants from Gilead Sciences, MSD, Pfizer and F2G, and non-financial support from OLM and IMMY, outside the submitted work. |
| T247 |
1149-1520 |
Sentence |
denotes |
BJA Rijnders was the investigator for studies supported by Gilead Sciences, Janssen-Cilag, MSD, Pfizer, ViiV; has received research grants from Gilead and MSD; was an invited speaker for Gilead, MSD, Pfizer, Jansen-Cilag, BMS; and an advisory board member for BMS, Abbvie, MSD, Gilead, Jansen-Cilag; he received travel support from BMS, Abbvie, MSD, Gilead, Jansen-Cilag. |
| T248 |
1521-1798 |
Sentence |
denotes |
RJM Brüggemann served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc. |
| T249 |
1799-1883 |
Sentence |
denotes |
All contracts were through Radboudumc, and all payments were invoiced by Radboudumc. |
| T250 |
1884-1970 |
Sentence |
denotes |
E Azoulay has received fees for lectures from Pfizer, Gilead, MSD, Alexion and Baxter. |
| T251 |
1971-2057 |
Sentence |
denotes |
His institution received research support from Fisher&Payckle, Jazz pharma and Gilead. |
| T252 |
2058-2361 |
Sentence |
denotes |
M Bassetti has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMèrieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher and The Medicine Company. |
| T253 |
2362-2508 |
Sentence |
denotes |
S Blot received research funding from Pfizer and MSD, travel support from Pfizer, MSD and Gilead, and is an invited speaker for Pfizer and Gilead. |
| T254 |
2509-2712 |
Sentence |
denotes |
T Calandra reported advisory board membership from Astellas, Basilea, Cidara, MSD, Sobi, ThermoFisher and GE Healthcare and data monitoring board membership from Novartis, all outside the submitted work. |
| T255 |
2713-2746 |
Sentence |
denotes |
Fees are paid to its institution. |
| T256 |
2747-3092 |
Sentence |
denotes |
CJ Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems. |
| T257 |
3093-3654 |
Sentence |
denotes |
OA Cornely is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. |
| T258 |
3655-3699 |
Sentence |
denotes |
T Chiller reported no conflicts of interest. |
| T259 |
3700-3744 |
Sentence |
denotes |
P Depuydt reported no conflicts of interest. |
| T260 |
3745-3846 |
Sentence |
denotes |
DR Giacobbe reported honoraria from Stepstone Pharma GmbH and an unconditional grant from MSD Italia. |
| T261 |
3847-3893 |
Sentence |
denotes |
NAF Janssen reported no conflicts of interest. |
| T262 |
3894-3968 |
Sentence |
denotes |
BJ Kullberg has been a scientific advisor for Amplyx, Cidara and Scynexis. |
| T263 |
3969-4136 |
Sentence |
denotes |
K Lagrou received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, travel support from Pfizer and MSD and speaker fees from Gilead, MSD, FUJIFILM WAKO. |
| T264 |
4137-4300 |
Sentence |
denotes |
C Lass-Florl received research funding from Pfizer, Gilead and Egger, travel support from Pfizer, MSD, and Gilead, and is an invited speaker for Pfizer and Gilead. |
| T265 |
4301-4407 |
Sentence |
denotes |
RE Lewis has received research support from Merck and has served as an invited speaker for Gilead, Cidara. |
| T266 |
4408-4584 |
Sentence |
denotes |
P Wei-Lun Liu has received research grants from MSD, Pfizer, and has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is an advisor to Pfizer, Gilead. |
| T267 |
4585-4722 |
Sentence |
denotes |
O Lortholary has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is a consultant for Gilead, Novartis and F2G. |
| T268 |
4723-4959 |
Sentence |
denotes |
J Maertens reported personal fees and non-financial support from Basilea Pharmaceuticals, Bio-Rad Laboratories, Cidara, F2G Ltd., Gilead Sciences, Merck, Astellas, Scynexis, and Pfizer Inc. and grants from Gilead Sciences, IMMY and OLM. |
| T269 |
4960-5011 |
Sentence |
denotes |
I Martin-Loeches reported no conflicts of interest. |
| T270 |
5012-5252 |
Sentence |
denotes |
MH Nguyen has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this study and served on advisory boards for Astellas, Merck, the Medicines Company, Scynexis and Shionogi. |
| T271 |
5253-5449 |
Sentence |
denotes |
TF Patterson reported grants from Cidara to UT Health San Antonio; personal fees from Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, Toyama and United Medical outside the submitted work. |
| T272 |
5450-5623 |
Sentence |
denotes |
TR Rogers has received grants from Gilead Sciences, lecture honoraria from Gilead Sciences and Pfizer Healthcare Ireland, and advisory board membership with Menarini Pharma. |
| T273 |
5624-5737 |
Sentence |
denotes |
JA Schouten has received unrestricted educational and research grants from MSD and has been an advisor to Pfizer. |
| T274 |
5738-5822 |
Sentence |
denotes |
All contracts were through Radboudumc, and all payments were invoiced by Radboudumc. |
| T275 |
5823-5942 |
Sentence |
denotes |
I Spriet has received unrestricted research grants, speaker fees and travel grants from MSD, Pfizer, Gilead and Cidara. |
| T276 |
5943-5991 |
Sentence |
denotes |
She has served in the advisory board for Cidara. |
| T277 |
5992-6101 |
Sentence |
denotes |
L Vanderbeke is supported by the Flanders Research Foundation (FWO Vlaanderen) through a doctoral fellowship. |
| T278 |
6102-6229 |
Sentence |
denotes |
J Wauters reported grants from Gilead Sciences, MSD and Pfizer, and non-financial support from MSD, outside the submitted work. |
| T279 |
6230-6293 |
Sentence |
denotes |
FL van de Veerdonk has served as an invited speaker for Gilead. |
